“Because of revolutionary genetic testing methods, we’re getting smarter round not only the diagnosis of prostate cancer but who needs surgery and which patients should watch their cancer. This is a huge large shift in this discipline,” said Dr Anup Ramani.

As presented at the 110th Annual Scientific Meeting at India Urological Association last week, prostate cancer screening needs a more intelligent approach. “I see hundreds of men every month and we’re already using this approach. The foundation stems from treating each affected person individually and now genetic testing can show even earlier how high a man, s risk for prostate cancer is,” noted Dr Anup Ramani.

The game changer here is the role genetic testing outperforms all through the whole process, from analysis to recurrence. If a man’s PSA is elevated, new genetic assessments along with the PHI, 4K rating, PcA3, and Prostate Biopsy can similarly suggest activity around the prostate as well as a guide whether to get a biopsy or no longer. If a biopsy is successful, the next step is directing the right prostate cancer treatment for each patient. Other genetic testing techniques such as Polaris, OncotypeDx, Prostavysion and trying out for hereditary PCa and genes like BRCA, will provide more information regarding the risk factors, growth rate, aggressiveness and threat of morbidity of cancer.

“Now that we’ve moved from Ultrasound to MRI, in combination with these genetic tests, we may, in reality, be to able to crack the code and diagnose aggressive prostate cancer earlier. And of course, these results in the right treatment route for each affected person,” said Dr Anup Ramani.

Next is treatment evaluation. If surgical treatment is suggested, the prostate gland can be analyzed to evaluate the probability of metastasis and/or biochemical recurrence the usage of the Genome Dx/Decipher test or following the trend of the patient’s PSA and how soon after surgical treatment it increases. If cancer comes again, radiation can be used as a secondary treatment for cases more likely to arise. Being able to identify risk factors in advance is a step forward.

“We cannot treat each cancer, along with Gleason rankings of 6, 7, or 8+, the equal. With prostate cancers, we need to individualize the care and now we will with new genetic trying out diagnostic tools. We can gather more information about the patient’s case at every step of the way,” stressed Dr Anup Ramani.

“Even similarly, these genetic tests will help us higher distinguish candidates for prostate cancer surgical operation as opposed to watchful waiting and if the ailment is more likely to recur.”

“Perhaps the future of prostate cancer prevention seems greater like breast most cancers nowadays. In the next 10 years, we can be recommending men to preemptively remove their prostate because the risk for the diseases is so excessive. Being able to smartly distinguish those patients from those with a much lower risk begins with genetic testing,” noted Dr Anup Ramani.

For a free consultation from Dr Anup Ramani- Best uro-oncologist and well known robotic surgeon.

Visit: [URL]https://www.indialaparoscopysurgerysite.com/consult-dr-anup-ramani-top-uro-oncology-robotic-surgeon-breach-candy-hospital-mumbai-india.php[/URL]

Call: +91 9373055368 to set up your free consultation.